Natural History of HIV Infection

Slide 1 · Natural History of HIV Infection

Acute infection • clinical latency • progression to AIDS

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives: Explain the course of untreated HIV infection

Trace infection from the mucosal portal to systemic viremia.

Explain how antiviral immunity produces partial control without eradication.

Interpret viral set point and CD4+ T-cell depletion across stages.

Recognize typical and atypical patterns of progression to AIDS.

Slide 3 · Three phases organize the natural history

Acute retroviral syndrome

Chronic infection / clinical latency

Clinical AIDS

The phases describe manifestations of infection, not abrupt biological switches.

The sequence reflects the untreated course.

Slide 4 · Clinical appearance is not equivalent to virologic activity

Clinical expression

Virologic and immunologic state

Acute: Short, systemic illness

Early peak of dissemination and viremia

Middle phase: Few or no symptoms

Persistent lymphoid replication and CD4+ loss

Advanced disease: Severe syndromes

Rising viral burden and failed host defense

A clinically silent interval is not a virologically silent interval.

Slide 5 · Initial infection begins at a mucosal portal

Mucosal epithelium

Mucosal lymphoid compartment

Memory

CD4+ T cell

Memory

CD4+ T cell

Dendritic

Cell

HIV

Entry and infection

Mucosal memory CD4+ T cells are early targets of infection and death.

A local event initiates broader infection of lymphoid tissue.

Slide 6 · Mucosal barrier integrity modifies susceptibility

Damage to the epithelium favors establishment of mucosal infection.

Defects in mucosal barrier function are additional predisposing factors.

Local entry conditions influence the efficiency of initial infection.

Slide 7 · Memory CD4+ T cells are abundant at the mucosal portal

Why they are vulnerable

Immediate consequences

Memory T cells constitute a large mucosal compartment.

Numerous infected cells die during early infection.

These cells are susceptible to HIV infection.

Mucosal lymphocyte depletion can be substantial.

Local infection directly injures the target-cell pool.

Blood counts do not reveal the full tissue injury.

Slide 8 · Early mucosal depletion precedes the full systemic picture

Infection of mucosal memory cells

Loss of many infected CD4+ cells

Reduction of local lymphocyte pool

A major immunologic injury can occur before overt AIDS.

Early damage is concentrated in tissue, not necessarily peripheral blood.

Slide 9 · Dendritic cells connect entry sites to lymph nodes

Mucosal entry site

Draining lymph node

Peripheral lymphoid tissue

DC

DC

CD4+

CD4+

Migration

Seeding

DCs can capture HIV at the site of entry and move to regional lymph nodes.

Direct DC-to-T-cell transfer promotes establishment of lymphoid infection.

Slide 10 · Lymph nodes become early amplification sites

HIV replication can be detected in lymph nodes within days of exposure.

The lymphoid compartment supports sustained viral multiplication.

Replication at these sites precedes broad hematogenous dissemination.

Slide 11 · Viremia follows lymphoid amplification

Virus replication in lymph nodes

High numbers of particles in blood

Widespread dissemination

Viremia denotes HIV in circulating blood.

It marks systemic spread rather than the initial local infection.

Slide 12 · Systemic dissemination seeds multiple immune compartments

Dissemination process

Host-cell targets

The bloodstream distributes virus beyond entry sites.

CD4+ helper T lymphocytes are infected.

Peripheral lymphoid tissues become infected.

Macrophages also become infected.

Infection becomes widely established.

Immune-system sites carry a substantial viral burden.

Slide 13 · Early blood sampling underrepresents tissue infection

Relatively few infected cells may initially be detected in blood.

Mucosal and lymphoid tissue infection can already be extensive.

Tissue-level immunopathology should not be inferred from blood-cell frequencies alone.

Slide 14 · Establishment of primary infection: The full causal sequence

Mucosal portal

Node amplification

Systemic viremia

Lymphoid seeding

The order explains why local infection has systemic consequences.

Host immune activation occurs in response to this disseminated infection.

Slide 15 · Viral cytopathic injury and host response coexist

Direct infection-related events

Host-response events

Susceptible mucosal CD4+ cells become infected.

HIV-specific cytotoxic T cells develop.

Infected cells die; Viral replication expands.

Antiviral antibodies appear.

Lymphoid tissue contains replicating virus.

Immune containment lowers circulating virus.

Slide 16 · Adaptive immunity restrains early viremia

Dissemination of HIV

Cellular + humoral responses

Lower but detectable viremia

The antiviral response is effective enough to lower circulating RNA.

A decline in viremia is not equivalent to clearance of infection.

Slide 17 · HIV-specific cytotoxic T cells emerge early

CD8+ cytotoxic T lymphocytes (CTLs) target HIV peptide-bearing infected cells.

A virus-specific CTL response is detectable approximately 2–3 weeks after infection.

The CTL response peaks around 9–12 weeks in the course depicted by Robbins.

Slide 18 · Antiviral humoral responses develop during primary infection

Antibodies to HIV emerge with seroconversion.

Seroconversion usually within 3–7 weeks of presumed exposure.

The humoral immune response peaks at about 12 weeks figure.

Slide 19 · Cellular and humoral responses have related but distinct roles

Cellular response

Humoral response

Virus-specific CD8+ CTLs arise within weeks.

Seroconversion marks development of antibodies.

CD8+ T-cell clones expand substantially.

Anti-HIV antibody responses increase during the acute phase.

CTLs contribute to early viral containment.

Antibodies accompany partial reduction of viremia.

Slide 20 · Acute viremia falls as immune containment develops

Circulating HIV rises during early dissemination.

Cellular and antibody responses reduce circulating viral production.

By approximately 12 weeks, viremia often falls to lower but detectable levels.

Slide 21 · Immune control is substantial but incomplete

High early viremia

Host antiviral responses

Residual viral replication

HIV remains established in lymphoid tissue.

The chronic phase begins despite partial immunologic control.

Slide 22 · Acute retroviral syndrome reflects dissemination and response

The illness accompanies the initial widespread spread of HIV.

Symptoms arise during the early period of host immune activation.

The clinical syndrome is nonspecific and self-limited in typical cases.

Slide 23 · The timing of acute illness is characteristically delayed

Textbook-described untreated natural history; Individual courses vary.

Typical onset 3–6 weeks after infection.

The syndrome usually resolves spontaneously over 2–4 weeks.

A mild or absent acute illness does not preclude established infection.

Slide 24 · Acute retroviral syndrome: Constitutional manifestations

Systemic findings

Interpretation

Fever and fatigue

Nonspecific expression of acute systemic illness

Sore throat and myalgia

Flu-like clinical presentation

Weight loss

Constitutional effect during acute infection

Slide 25 · Acute retroviral syndrome: Accompanying manifestations

Additional feature

Clinical context

Rash

May accompany systemic illness

Cervical adenopathy

Reflects lymphoid/systemic involvement

Diarrhea or vomiting

Possible gastrointestinal symptoms

Slide 26 · Clinical exercise: A flu-like illness after exposure

CLINICAL VIGNETTE

Several weeks after a suspected exposure, a patient develops fever, sore throat, myalgia, cervical lymphadenopathy and rash.

Which phase of infection is compatible with this presentation?

The symptom cluster and timing fit the acute retroviral syndrome; Clinical features alone are not diagnostic.

Slide 27 · A resolving illness does not mean the virus has disappeared

What often improves

What persists

Fever and constitutional symptoms subside.

HIV remains in lymphoid compartments.

Acute viral syndrome is typically self-limited.

Some viral replication continues.

Clinical appearance may return to normal.

The individual enters clinical latency, not cure.

Slide 28 · Plasma HIV RNA is a marker of active systemic infection

The measurable amount of HIV-1 RNA in blood is the viral load.

Its level changes rapidly during primary infection.

It has value for interpreting disease evolution and virologic activity.

Slide 29 · The viral set point follows the acute decline

Early high viremia

Partial immune containment

Relatively stable viral set point

The set point describes a steady-state balance, not absence of virus.

It may remain approximately stable in an untreated patient for several years.

Slide 30 · The set point reflects competing biological processes

Persistent HIV

Replication

Partial host immune

Containment

Steady-state viremia

(viral set point)

Competing effects

The set point is a dynamic equilibrium, not virologic eradication.

A higher sustained viral burden predicts more rapid subsequent CD4+ loss.

Slide 31 · The viral set point predicts subsequent immunologic decline

The steady-state viral load is a prognostic correlate of HIV progression.

Higher sustained viral burdens are associated with faster CD4+ depletion.

The host–virus balance helps explain variable untreated trajectories.

Slide 32 · Viral load and CD4+ count answer different questions

Plasma HIV RNA

CD4+ T-cell count

Reflects circulating viral burden.

Reflects immune-system depletion.

Tracks viral replication and its containment.

Declines across progressive untreated infection.

Set point has prognostic relevance.

Helps identify advanced immunodeficiency.

These measurements are complementary, not interchangeable.

Slide 33 · Robbins reproduces historical CDC CD4+ categories

Category

CD4+ T cells/μL

Historical interpretation

1

≥500

Higher count category

2

200–499

Intermediate count category

3

<200

Severely depleted category

CDC 1993 classification reproduced by the textbook; Not a current ART initiation rule.

Slide 34 · Loss of CD4+ cells reflects waning immune containment

Persistent HIV infection reduces the size of the helper T-cell pool.

CD4+ loss impairs the host ability to coordinate effective immune responses.

A declining CD4+ count signals increasing immunologic vulnerability.

Slide 35 · Untreated natural history: Two changing measures

High acute viral RNA / initial injury

Lower set point / gradual CD4+ decline

Rising RNA / profound CD4+ depletion

This is a qualitative sequence, not measured trajectories or rates.

Viremia and immune-cell loss need not change in parallel at every moment.

Slide 36 · Clinical latency is defined by symptoms—not absent replication

Patients frequently have few or no overt manifestations of HIV infection.

Lymph nodes and spleen remain sites of HIV replication and cell destruction.

Peripheral blood CD4+ T-cell counts continue to decrease over time.

Slide 37 · Lymphoid organs are central to the chronic phase

Lymph nodes

Spleen

Major sites of persistent viral multiplication.

Another secondary lymphoid site of replication.

Contain susceptible and infected T cells.

Infection and immune-cell destruction persist.

Ongoing cell turnover can be extensive.

Systemic lymphoid damage may accumulate.

Slide 38 · Peripheral blood is only a small part of the T-cell system

That most T cells reside in secondary lymphoid organs.

The burden of infected cells may therefore be greater in lymphoid tissue than blood.

Blood tests provide an important but incomplete view of tissue events.

Slide 39 · Tissue infection can far exceed circulating-cell infection

Lymphoid tissue

Peripheral blood

Large population of CD4+ T cells.

Many circulating T cells are not infected.

Ongoing viral production and target-cell loss.

Fewer infected cells may be sampled.

Central site of chronic immunopathology.

Absolute CD4+ counts still track immune decline.

Slide 40 · Chronic infection involves continuing cell replacement and loss

Repeated infection

CD4+ T-cell death

Compensatory cell replacement

Early in chronic disease, new T cells can replace much of the loss.

Persistent turnover does not imply stable long-term immune function.

Slide 41 · Early compensation can conceal cumulative immune damage

Continuous cell destruction may initially be matched by replenishment.

Peripheral CD4+ cell counts can decline slowly rather than abruptly.

Clinical wellness may coexist with substantial tissue turnover.

Slide 42 · Progressive decline reflects a self-amplifying cycle

Persistent viral infection

Ongoing T-cell depletion

Diminished immune containment

More viral activity

Years of cumulative imbalance erode both lymphoid and circulating CD4+ pools.

Ultimately, replacement no longer offsets sustained losses.

Slide 43 · Rising viral burden accompanies failing immune control

The proportion of surviving CD4+ cells infected with HIV may increase.

Viral burden per infected CD4+ cell may also rise.

Plasma HIV RNA increases when control of viral replication deteriorates.

Slide 44 · Why HIV may escape immune containment

Loss of host capacity

Viral evasive properties

CD4+ cells needed for effective adaptive immunity are depleted.

Antigenic variation reduces immune recognition.

The ability to sustain effective antiviral responses weakens.

MHC class I down-modulation may impair CTL recognition.

Opportunistic organisms exploit this failure.

Coreceptor usage may change in some patients.

Slide 45 · Antigenic variation challenges sustained antiviral recognition

Viral variation can alter immune targets over time.

Previously generated adaptive responses may become less effective.

This contributes to continued replication despite host immunity.

Slide 46 · MHC class I down-modulation can weaken CTL recognition

HIV may down-modulate MHC class I molecules on infected cells.

This may reduce presentation of viral antigens to CD8+ CTLs.

Incomplete CTL recognition facilitates persistence of infected cells.

Slide 47 · Coreceptor evolution may accompany faster immune decline

Early predominance of CCR5 use

Possible CXCR4 or dual use

Greater T-cell infection and CD4+ loss

The proposed switch does not occur identically in every patient.

The source links coreceptor switching with more rapid CD4+ decline.

Slide 48 · The chronic phase has more than one clinical phenotype

Asymptomatic infection

Minor associated illness

Few or no apparent manifestations.

Oral or vaginal candidiasis can appear.

Continuing lymphoid replication.

Herpes zoster may occur.

Progressive loss of CD4+ cells may be silent.

Tuberculosis and immune thrombocytopenia are also noted.

Slide 49 · Minor conditions may signal waning host defenses

Finding during chronic infection

Clinical significance in Robbins

Oral candidiasis (thrush)

Opportunistic infection during waning cellular immunity

Herpes zoster

Possible infection in the chronic phase

Tuberculosis

Can occur relatively early; region-dependent burden

Autoimmune thrombocytopenia

Immune dysregulation may accompany infection

Slide 50 · Transition to AIDS represents failure of immune defense

CD4+ depletion eventually reaches a clinically consequential level.

Viral load increases dramatically as host control breaks down.

Serious AIDS-associated diseases become likely.

Slide 51 · The shift from latency to AIDS is mechanistically coherent

Continued CD4+ T-cell erosion

Breakdown of effective host defense

Severe opportunistic or neoplastic disease

There is no requirement for a new infection with HIV to cause this transition.

The process reflects cumulative loss of containment of the established infection.

Slide 52 · Advanced infection produces persistent constitutional illness

Prolonged fever, fatigue, and weight loss may develop.

Diarrhea and generalized lymph-node enlargement may accompany disease.

The pattern reflects severe systemic illness and impaired immunity.

Slide 53 · Clinical AIDS is recognized through severe indicator conditions

Major category

Illustrative consequences

Serious opportunistic infections

Disease in the setting of advanced immune dysfunction

Secondary neoplasms

Tumors associated with profound immune impairment

Clinical neurologic disease

Central nervous system manifestations of HIV-related illness

Slide 54 · Persistent HIV creates both infectious and noninfectious damage

Infectious burden

Other consequences

Susceptibility to opportunistic pathogens increases.

Secondary neoplasms can emerge.

Organ-specific infections may become life threatening.

Neurologic disease can become clinically manifest.

Protection against latent pathogens weakens.

Severe constitutional symptoms accompany immunodeficiency.

Slide 55 · Typical progression is variable, even without therapy

Progression to AIDS after about 7–10 untreated years in most patients.

This is a historical untreated-course description, not an individual prediction.

Both unusually rapid and unusually slow courses are recognized.

Slide 56 · Patterns of untreated progression

Pattern

Natural-history feature

Interpretation

Typical progressor

Chronic interval often 7–10 years

Gradual erosion of host defense

Rapid progressor

Middle phase may shorten to 2–3 years

Accelerated immune decline

Long-term nonprogressor

Sustained clinical stability for ≥10 years

Unusually effective control

Elite controller

Exceptionally low untreated viremia

Rare degree of viral containment

These are qualitative, textbook-described untreated phenotypes; Definitions vary by study.

Slide 57 · Rapid progressors compress the chronic interval

A minority develops advanced disease more quickly than the typical course.

A chronic phase of only 2–3 years after primary infection.

A short interval still follows the same broad mechanism of immune deterioration.

Slide 58 · Long-term nonprogression is uncommon

Approximately 1% who remain asymptomatic for a decade or longer without ART.

CD4+ T-cell counts can remain stable despite established infection.

Low viral loads distinguish these individuals from typical progression.

Slide 59 · Long-term nonprogressors and elite controllers are related labels

Long-term nonprogressors

Elite controllers

Long untreated clinical stability.

Very low untreated plasma HIV RNA.

Typically low measurable HIV RNA.

Exceptional ability to contain replication.

Stable CD4+ cells are a central feature.

Immune correlates remain incompletely defined.

Slide 60 · Effective immune control is not explained by a single mechanism

Slow progressors are heterogeneous in host and viral characteristics.

Many isolates do not have major qualitative viral defects.

The textbook does not identify one universal correlate of protection.

Slide 61 · Potent T-cell responses may accompany slow progression

CD4+ immune responses

CD8+ immune responses

Higher HIV-specific helper T-cell responses in some individuals.

Strong antiviral cytotoxic responses may persist.

Responses may be maintained over years.

Responses may be maintained during long untreated infection.

Helper functions support broader immunity.

They contribute to sustained containment.

Slide 62 · HLA genetic variation is associated with progression heterogeneity

Certain inherited HLA alleles correlate with slower progression.

The proposed explanation is more potent antiviral T-cell recognition.

Association does not establish a universal predictive genotype.

Slide 63 · Clinical exercise: Apparent health with falling CD4+ cells

CLINICAL VIGNETTE

An untreated patient reports no symptoms. Over serial visits, the peripheral CD4+ T-cell count declines while HIV RNA remains detectable.

Does the absence of symptoms indicate viral latency?

No. “Clinical latency” permits ongoing lymphoid replication and progressive immune injury.

Slide 64 · Clinical exercise: Progression with rising HIV RNA

CLINICAL VIGNETTE

After years of untreated infection, a patient develops weight loss, persistent fever and an opportunistic infection; HIV RNA has increased.

What integrated mechanism accounts for the change?

Progressive CD4+ loss weakens containment, permitting increased viral burden and advanced disease.

Slide 65 · Integrating natural history into one explanatory chain

Mucosal infection

Systemic spread

Partial immune control

Cumulative immune failure

Acute syndrome corresponds to early spread and antiviral response.

Clinical latency conceals ongoing CD4+ attrition until severe disease appears.

Slide 66 · Comparison: Acute infection, latency and AIDS

Feature

Acute infection

Clinical latency

AIDS

Virologic pattern

Dissemination; high viremia

Persistent replication

Marked viral increase

CD4+ cells

Early mucosal loss

Continuing depletion

Profound loss

Clinical pattern

Flu-like syndrome possible

Few/no symptoms

Severe associated disease

Host control

Developing responses

Partial containment

Control fails

Qualitative comparison; Clinical phenotype and rate of progression vary.

Slide 67 · Principal mechanistic insights

The mucosal and secondary lymphoid compartments determine early and chronic pathobiology.

Immune responses suppress viremia but do not eliminate established infection.

Cumulative CD4+ depletion converts clinical latency into advanced immunodeficiency.

Host and viral heterogeneity explain unusual progression phenotypes.

Slide 68 · Final clinical interpretation

A self-limited acute syndrome can still be followed by persistent HIV infection.

Clinical wellness must not be confused with the absence of ongoing immune injury.

Viral set point and CD4+ T-cell trajectory provide complementary biological information.

The classic untreated course is fundamentally altered by effective ART.

Slide 69 · Primary reading and historical framework

Robbins, Cotran & Kumar

Pathologic Basis of Disease, 11th edition (2026)

Diseases of the Immune System

Natural History of HIV Infection

The timelines and immune-cell categories discussed here represent the textbook’s historical natural-history framework; they are not a contemporary treatment guideline.